Key result
ECMO in severe COVID-19 is linked to longer ICU stays and distinct multi-omics metabolic signatures.
Why the study?
Does extracorporeal membrane oxygenation (ECMO) alter clinical, proteomic, and metabolomic biochemical signatures compared to non-ECMO care in critically ill COVID-19 ICU patients?
Cohort (n=52)
Does extracorporeal membrane oxygenation (ECMO) alter clinical, proteomic, and metabolomic biochemical signatures compared to non-ECMO care in critically ill COVID-19 ICU patients?
Multi-omics profiling of critically ill COVID-19 patients reveals that ECMO support is associated with a distinct molecular signature of oxidative stress, lipidomic reprogramming, immune modulation, and membrane injury.
Answers are grounded in this paper and cite their sources.
ECMO in critically ill COVID-19 warrants further study; leaves open its clinical utility pending higher-level evidence.
Extracorporeal membrane oxygenation (ECMO) is a rescue therapy for severe COVID-19-associated respiratory failure, yet its molecular impact on critically ill patients remains insufficiently characterized. In this retrospective study of 52 ICU patients, clinical, proteomic and metabolomic data were associated to identify ECMO-associated biochemical signatures between ECMO and non-ECMO in discharged patients, deceased patients, and all patients regardless of outcome. Clinical data showed that ECMO recipients exhibited greater physiological derangements, including higher leukocyte and neutrophil counts and prolonged IMV and ICU stays. Proteomic analysis revealed ECMO-associated perturbations in cytokine signaling, myeloid activation, and antigen-presentation pathways. Among survivors, ECMO was linked to reduced HLA class II expression and elevated CSF3, suggesting dampened antigen presentation with concurrent granulopoeitic stimulation. In non-survivors, ECMO was associated with increased inflammatory-metabolic mediators such as FASN and PTGIS, consistent with mitochondrial dysfunction, lipid turnover, and endothelial stress. Metabolomics revealed a coherent ECMO-associated metabolic phenotype across comparison. Key discriminating metabolites include sphingomyelin, lysophosphatidic acid, tocotrienol- and steroid-derivates, collectively indicating redox imbalance, membrane remodeling, pro-inflammatory lipid signaling, and steroid-metabolic dysregulation. Conversely, depletion of cysteinylglycine pointed to impaired glutathione-dependent antioxidant defense. Together, these multi-omics alterations define a consistent ECMO-associated molecular signature across study comparisons characterized by oxidative stress, lipidomic reprogramming, immune modulation, and structural membrane injury. These findings provide a molecular framework for understanding ECMO-related physiological stress and may provide a basis for prospective validation in larger cohorts of critically ill COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
Fonseca et al. (2026) conducted a cohort in Critically ill COVID-19-associated respiratory failure (n=52). Extracorporeal membrane oxygenation (ECMO) vs. Non-ECMO critically ill COVID-19 ICU patients was evaluated on ECMO-associated clinical, proteomic, and metabolomic signatures. ECMO in 52 critically ill COVID-19 ICU patients was associated with prolonged IMV/ICU stays and distinct multi-omics signatures of oxidative stress, lipidomic reprogramming, and immune modulation.
Synapse has enriched 10 related papers. Consider them for comparative context: